New combo therapy aims to zap eye cancer with fewer side effects
NCT ID NCT07247383
Summary
This study is testing if a new drug, orelabrutinib, works better and is safer when combined with either very low-dose radiation or another drug called rituximab for a rare, slow-growing lymphoma around the eye. It involves 39 adults with early-stage disease who haven't had prior treatment. The goal is to control the cancer effectively while reducing the eye damage that can come from standard radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
2ndAffiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.